Wall Street brokerages forecast that Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) will announce earnings of ($0.24) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Galmed Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.14). Galmed Pharmaceuticals reported earnings per share of ($0.17) in the same quarter last year, which would suggest a negative year over year growth rate of 41.2%. The business is expected to issue its next earnings report on Thursday, August 1st.

On average, analysts expect that Galmed Pharmaceuticals will report full-year earnings of ($1.14) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($0.64). For the next year, analysts expect that the company will post earnings of ($1.45) per share, with EPS estimates ranging from ($2.06) to ($0.73). Zacks’ EPS averages are a mean average based on a survey of analysts that cover Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.02.

A number of brokerages have commented on GLMD. Laidlaw began coverage on Galmed Pharmaceuticals in a research note on Monday, July 22nd. They set a “buy” rating and a $25.00 price objective on the stock. Maxim Group restated a “buy” rating and set a $60.00 price objective on shares of Otter Tail in a research note on Tuesday, May 7th. HC Wainwright set a $31.00 price objective on Kura Oncology and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Finally, ValuEngine cut WideOpenWest from a “hold” rating to a “sell” rating in a research note on Friday, June 28th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Galmed Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $28.17.

Several large investors have recently added to or reduced their stakes in GLMD. Northern Trust Corp raised its stake in Galmed Pharmaceuticals by 16.3% during the fourth quarter. Northern Trust Corp now owns 12,215 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 1,715 shares in the last quarter. BlackRock Inc. acquired a new stake in Galmed Pharmaceuticals during the fourth quarter valued at approximately $33,000. ARK Investment Management LLC raised its stake in Galmed Pharmaceuticals by 31.6% during the first quarter. ARK Investment Management LLC now owns 53,749 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 12,905 shares in the last quarter. Raymond James & Associates raised its stake in Galmed Pharmaceuticals by 19.0% during the fourth quarter. Raymond James & Associates now owns 86,201 shares of the biopharmaceutical company’s stock valued at $589,000 after buying an additional 13,764 shares in the last quarter. Finally, Delek Group Ltd. acquired a new stake in Galmed Pharmaceuticals during the first quarter valued at approximately $173,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

GLMD stock traded down $0.01 during trading on Monday, reaching $6.08. 19,100 shares of the stock traded hands, compared to its average volume of 89,477. The firm’s 50 day simple moving average is $6.50. Galmed Pharmaceuticals has a 52-week low of $5.48 and a 52-week high of $14.65. The company has a quick ratio of 36.11, a current ratio of 36.11 and a debt-to-equity ratio of 0.01. The firm has a market cap of $126.54 million, a price-to-earnings ratio of -11.28 and a beta of 2.67.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Read More: What is a Buy-Side Analyst?

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.